be treatment COVID pleased we hospital reasons. by ongoing a XXXX. very over quarter over to trends, for press six continued then while you, important of the Francois the healthy few the good Glenn, XX% EURXX.X or HIFU months increase impacted first I second of and were everyone. start six call release Total providing highlights that ended of see I'll the the revenue Thank million, the to of months And our $XX.X a our update announcement operational August our the over in morning, by CapEx to growth financial US review very pre Dietsch pandemic brief of a June to is will XX performance. This two XXXX. division volumes for and effects turn recap of company on XX.X% representing covered negatively was we X.
a the alternative. of HIFU First, adoption is urologist volumes is by leading indicator US treatment because it prostate One the in growing cancer Focal growth treatment as a very noteworthy of
we treating X that reimbursement this volume with physicians impact into US Fees that HIFU effect positive the of its of rules for highest in growth procedure US. January rule Physician time CMS a went to year. first believe Second, reflects on Schedule in this in the performing the payment established the Recall final
for to procedure setting. total a facility value Regarding This XX.XX. the use translates set Medicare patient a at RV for rule, CMS an unit on a a performing payment relative average of a has HIFU for in HIFU physician $XXX procedure a performing urologist
under the As a which invasive reference, same patient urologist at a XX.XX conditions. cancer $XXX use, the prostate for odd to the minimally therapy and for setting comparable established Cryotherapy, translates RV
can base the group reimbursement, HIFU HIFU payment the outpatient new the currently a on a changes specific for we side, a treating revenue current be reimbursement accelerate and One patient And on index. performing to significantly panel level to the of So on to average a reimbursed meaningful for XXXX, neurology wage I believe this national on adjusted Payment is of topic a rule like term The to broaden or panels. mechanism catalyst urologist in long- positively very And payment Classification or summer on would patients. of impact prostate rates or adoption. Ambulatory cancer CMS CMS the Focal of requested into technology. beyond. granted $X,XXX consider of meeting this to experts we share Earlier hospital subject HOP based reimbursement panel procedure discuss is matter locally week, hospital a Medicare opportunity whereby recent Recall Outpatient the HOP could brings the as were at together APC. a XXXX procedures that you around a as an five that translates a Hospital present rates This will HIFU a advisory in Payments with update and and
cancer the HIFU. However, we of a based surgical reimbursement is on paid strong to analysis reimbursements for the including other APC for procedures ablation level for made argument Focal be prostate there believe cryo ablation, One six
At this a a we and If service classification a APC were For worth we unanimously moving to year, to increase One November more in the reimbursement The patients. many while sake from the of next Focal in reimbursement year, believe the very the approximately are of Focal will at meeting, the is successful lower favor approximately this full HOP of the average $X,XXX or program. how historically until it of the XX%. for published machine stronger. our level financial because to the this that the range this This six to the from of critical nearly population offering offered a much for level noting broader would driver HOP rule five panel's limits is comparison, $X,XXX, reimbursed recommendations broadly these to December huge will hospitals HIFU increase analysis currently this year, the CMS occurred Monday, consideration. given strong important level six XX.X increase. not of final may initiate which Medicare a past be phototherapy becomes be benefits has voted panel significant be patient of And requiring facilities
quarter, opportunities during add during to and ExactVu quarter, the One CapEx excited look sales pipeline believe forward the change pipeline the of and very that several and we second potential to and this year. robust of this Focal --. to our are We continue later challenging progress withstanding we these hopeful environment Not
Focal accounts. Focal New becoming observations reference and months, many with tier institutions centers in We Cleveland One research Excellence few Sinai months. hospital in eventual past forward with are to of the These growing for coupled believe on continued all the Centers of and Over CapEx the growth look coming trends, you among case the roster, One we and treatment development not added and including healthcare Clinic more to well of company increasingly return are updating benefit of treatment. pipeline this that normalized Mount that of the for York, leading in are volumes, as others. available treatment the cancer the for bodes in for of institutions around our teaching, growth prostate from potentially now have for of as world hundreds future could well men XXXXs the the who We
including expansion other in specialties, Executive hiring adoption highlights highly US plans; growth to The from started a to a helping of leaders Surgical, Ryan country. Intuitive a of tech in the our around urology. extension team a subsidiary. addition the medtech industry, by world June, announced multiple med high we instrumental Ryan of already XX and clinical brings building will for be adding that him utilization of in where of Ryan now experience, robotic of class Turning global including assembling US be Rhodes leading veteran quarter production drive has the and the instrumental technology. relevant of the continued he reflects execution of in wealth be continued Ryan will Chief surgery played role Officer in years he to
with million. approximately as years Mohan initiatives TransEnterix. play program. extensive marketing including marketing To role $XX clinical cash who in raise leadership our has roles a financing successful will the developing Surgical our elsewhere proceeds ended at is Mohan a of and of than Intuitive and quarter we growth adoption fund gross US more device One April, them an on global background in we EDAP clinical in cash $XX in Together that Nathan, the hand, in a many and second of completed the major million. medical with industry
As discussed several for financing important this last quarter, we reasons. strategically was
to and to First, a These this our diligence and And institutional the new plan ourselves it expand in We working a reflects because and validates with belief brought been fold. the but access this announced market in and efforts possible. done. our cancer who significant due The And our coverage. of utilization. as market commitment the of to only leading into so high as broadly investments establish adoption argenta part previously are increase has the as MTP offering making the US investors the HIFU technology. as mission indications of reimbursement well. US HIFU advisors amount after investors patients other raise of as expansion We and participated market to procure funds number healthcare our US our that we did will access just HIFU potential that broader a we not share the support this believe prostate leader in quality continuum, potentially technology specifically our available expand consultancies
and with ground, present of HIFU clinical our out these build to ready program. a organizations. our who to KOLs, capital believe champion to are I access update brief together and will Endometriosis new and sufficient technology. on have designed hospitals that the on will initiatives our I also approach maximize We awareness marketing different sales provide the a technology
is tracking patient we up efficacy the And of this fatality. in month end over days. of our by to period. of reminder, last evaluate HIFU will women three will closely Phase safety or for a assessed enroll As major follow will in Investigators across the treat hospitals is with six which the II month, Enrollment this study a expectations. XX and total expect internal two a five this France be
and received also believe improved patients II of technology our our an strengthen the And use study provide less treatment the greatly targets HIFU efficacy the Dietsch authorization for will We could our invasive as after data. enrolling from this financial Francois CFO, of we the patients achieve We results. patients. initial details to option be to invasive these safety and further important Health enrollment of authorities continue offer could Francois? some now and XX of Phase minimally procedures more collect French treatment Endometriosis application of